Inclusion Criteria:

- Patients with AML, de Novo or secondary after Myelodysplasy, or with therapy-induced
AML after healed primary malignom; or refractory anemia with excess of blasts in
transformation (RAEB-t); the diagnosis must be confirmed morphological, cytochemical
and with immunological phenotyping

- Cytogenetical tests must be performed for each patient

- Age: 16 - 60 years

- All patients have to be informed about the character of the study. Written informed
consent of each patient at study entry.

Exclusion Criteria:

- Organic insufficiency: Insufficiency of the kidneys (Crea > 1.5 x upper normal serum
level), or insufficiency of the liver (bilirubin, SGOT or AP > 2 x upper normal serum
level) uncaused by the AML; severe obstruction or restrictive ventilation disorder,
heart failure with a ejection fraction < 0.5

- Secondary malignom

- Other severe diseases

- Pregnancy

- Participation in an concurrent clinical study